{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-121533","form_type":"8-K","ticker":"CAMP","cik":"0001736730","company_name":"Camp4 Therapeutics Corp","filed_at":"2024-11-21T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.407861+00:00","generated_at":"2026-05-29T21:00:11.512104+00:00","sec_items":["2.02","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"CAMP4 reports Q3 net loss $13.5M, completes IPO raising $82.1M, and signs BioMarin collaboration","bullets":["Q3 net loss $13.5M vs $11.7M in prior year; R&D $9.7M, G&A $3.8M.","Completed IPO in Oct 2024: 6.82M shares at $11.00, gross proceeds $82.1M (including partial underwriter option).","Entered strategic research collaboration with BioMarin valued at over $370M in milestones and royalties.","Phase 1 SAD portion completed; safety data expected Q1 2025, MAD biomarker data in H2 2025.","Cash $2.5M as of Sep 30, 2024; pro forma with IPO proceeds well-positioned to support development."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-121533","json":"https://secwatch.observer/filing/0001104659-24-121533.json","markdown":"https://secwatch.observer/filing/0001104659-24-121533.md","text":"https://secwatch.observer/filing/0001104659-24-121533.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1736730/000110465924121533/0001104659-24-121533-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1736730/000110465924121533/tm2428967d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-29T21:00:11.512104+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}